Head-to-head evidence
adalimumab-adbm (Cyltezo) vs CT-P13
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
CT-P13 · Inflectra / Remsima
Marketed by Celltrion
NCT02096861 · Phase 3 · completed
Randomized, double-blind Phase 3 non-inferiority trial of CT-P13 against originator infliximab in biologic-naive active Crohn's disease (n=220). The primary endpoint, CDAI-70 response at Week 6, met non-inferiority: the lower bound of the 95% CI (-16.9%) was above the -20% margin.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02137226 · Phase 3 · completed
The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.
CT-P13 · Inflectra / Remsima
Marketed by Celltrion
NCT01217086 · Phase 3 · completed
The study was randomized, double-blind, and actively controlled with Remicade in 617 participants. However, its primary endpoint was pharmacokinetic equivalence, a surrogate measure, and the registry does not report whether the equivalence comparison was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · CT-P13's landscape